Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S4.87
P/E—
Fwd P/E22.15
PEG1.80
52W— – —
RSI—
Target$645.15 (+5.8%)
Beta0.85
Div0.30%
Loading chart…
RSI ()
Loading patterns…
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 54
Overbought · 100
Signal
Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
8Bullish
4Bearish
0Neutral
Momentum Signals 12
▲ MACD Bullish Crossover
▲ Bull Flag
▲ Bull Flag
▲ MACD Bullish Crossover
No major reversal patterns in the last 4 months — showing momentum signals only.
View overlays on the price chart via Overview tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$645.15
+5.8% upside
Low $520
—
High $750
Consensus
Current price
Wall Street Analyst Ratings
Sort by
| Firm | Rating | Change | Action | Date |
|---|
Profitability
Gross Margin
40.99%Last 12 Months
Operating Margin
18.75%Last 12 Months
Return on Equity
13.51%Last 12 Months
Revenue Growth
10.50%Year over Year
Free Cash Flow
6.24BLast 12 Months
Free Cash Flow Yield
—Last 12 Months
Balance Sheet
Debt / Equity
80.58Most Recent Quarter
Current Ratio
1.55Most Recent Quarter
Cash
4.06BMost Recent Quarter
Total Debt
42.55BMost Recent Quarter
Net Debt
—Most Recent Quarter
How TMO Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 225.48B |
| Enterprise Value | 264.09B |
| Trailing P/E | 32.47 |
| Forward P/E | 22.15 |
| PEG Ratio (5yr) | 1.80 |
| Price/Sales (ttm) | 4.87 |
| Price/Book (mrq) | 4.28 |
| EV/Revenue | 5.70 |
| EV/EBITDA | 22.50 |
Share Statistics
| Avg Vol (3m) | 2.02M |
| Shares Outstanding | 369.75M |
| Float | 368.82M |
| % Held by Insiders | 0.13% |
| % Held by Institutions | 94.08% |
| Short Ratio | 3.37 |
| Short % of Float | 1.54% |
Profitability
| Gross Margin | 40.99% |
| Operating Margin (ttm) | 18.75% |
| Profit Margin | 15.04% |
| Return on Assets (ttm) | 5.13% |
| Return on Equity (ttm) | 13.51% |
Income Statement
| Revenue (ttm) | 46.34B |
| Revenue Growth (yoy) | 10.50% |
| Gross Profit (ttm) | 18.99B |
| EBITDA | 11.74B |
| Net Income (ttm) | 6.97B |
| Diluted EPS (ttm) | 18.78 |
| EPS Growth (yoy) | 9.40% |
Balance Sheet
| Total Cash (mrq) | 4.06B |
| Total Debt (mrq) | 42.55B |
| Debt / Equity (mrq) | 80.58 |
| Current Ratio (mrq) | 1.55 |
| Book Value / Share | 142.47 |
| Operating CF (ttm) | 9.01B |
| Free Cash Flow (ttm) | 6.24B |
Trading & Dividends
| Beta (5Y) | 0.85 |
| 50-Day MA | 576.56 |
| 200-Day MA | 536.52 |
| Fwd Dividend Yield | 0.31% |
| Payout Ratio | 9.69% |
Income
Dividend Yield
0.30%Last 12 Months
Annual Rate
1.88Forward
Payout Ratio
9.69%Last 12 Months
Dividend History
Payout Ratio (Last 12 Months): 9.69%
Monthly Dividends
Ownership Breakdown
Institutional 94.08%
Insider 0.13%
Public 5.8%
Short Interest
1.54% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in TMO in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Price | Value |
|---|